Having identified the condition, Mayo Clinic researchers continue to study MGUS to better understand it and to improve treatment options. Specific efforts involve determining risk factors for developing the condition, how these risk factors might influence treatment, and how to prevent progression of MGUS to blood cancers and other conditions.

Doctors and scientists in the Hematologic Malignancies Program of the Mayo Clinic Cancer Center are working on improving the diagnosis and treatment of myeloma and other blood disorders.


See a list of publications by Mayo Clinic doctors on monoclonal gammopathy of undetermined significance (MGUS) on PubMed, a service of the National Library of Medicine.